Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Protagonist Therapeutics (NASDAQ:PTGX) announced its participation in three major investment conferences in September 2025. CEO Dinesh V. Patel, Ph.D., will attend Citi's 2025 Biopharma Back to School Summit (September 2-3), H.C. Wainwright 27th Annual Global Investment Conference (September 8-10), and BofA 11th Annual World Medical Innovation Forum (September 15-17).
The CEO will participate in fireside chats at Citi's and H.C. Wainwright's events, scheduled for September 3 and September 9, respectively. At BofA's forum, he will join a panel discussion on "Immunology: Creating the next blockbuster in I&I" on September 16. Webcasts will be available for replay on the company's Investor Relations webpage.
Protagonist Therapeutics (NASDAQ:PTGX) ha annunciato la partecipazione a tre importanti conferenze per investitori a settembre 2025. L'amministratore delegato Dinesh V. Patel, Ph.D., sar脿 presente al Citi's 2025 Biopharma Back to School Summit (2-3 settembre), al H.C. Wainwright 27th Annual Global Investment Conference (8-10 settembre) e al BofA 11th Annual World Medical Innovation Forum (15-17 settembre).
Il CEO prender脿 parte a sessioni di conversazione informale (fireside chat) agli eventi di Citi e H.C. Wainwright, previste rispettivamente per il 3 e il 9 settembre. Al forum BofA, parteciper脿 a un panel intitolato "Immunology: Creating the next blockbuster in I&I" il 16 settembre. Le webcast saranno disponibili in replay nella sezione Investor Relations del sito aziendale.
Protagonist Therapeutics (NASDAQ:PTGX) anunci贸 su participaci贸n en tres importantes conferencias para inversores en septiembre de 2025. El director ejecutivo Dinesh V. Patel, Ph.D., asistir谩 al Citi's 2025 Biopharma Back to School Summit (2-3 de septiembre), al H.C. Wainwright 27th Annual Global Investment Conference (8-10 de septiembre) y al BofA 11th Annual World Medical Innovation Forum (15-17 de septiembre).
El CEO participar谩 en charlas informales (fireside chats) en los eventos de Citi y H.C. Wainwright, programadas para el 3 y el 9 de septiembre respectivamente. En el foro de BofA se unir谩 a un panel sobre "Immunology: Creating the next blockbuster in I&I" el 16 de septiembre. Las retransmisiones web estar谩n disponibles para ver en la p谩gina de Investor Relations de la compa帽铆a.
Protagonist Therapeutics (NASDAQ:PTGX)電� 2025雲� 9鞗旍棎 鞐措Μ電� 欤检殧 韴瀽 旎嵓霟办姢 3瓿踌棎 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 斓滉碃瓴届榿鞛� Dinesh V. Patel 氚曥偓電� Citi's 2025 Biopharma Back to School Summit (9鞗� 2-3鞚�), H.C. Wainwright 27th Annual Global Investment Conference (9鞗� 8-10鞚�), BofA 11th Annual World Medical Innovation Forum (9鞗� 15-17鞚�)鞐� 彀胳劃頃� 鞓堨爼鞛呺媹雼�.
CEO電� Citi鞕� H.C. Wainwright 頄夓偓鞐愳劀 臧侁皝 9鞗� 3鞚缄臣 9鞗� 9鞚检棎 歆勴枆霅橂姅 韺岇澊鞏挫偓鞚措摐 毂勴姼(fireside chat)鞐� 彀胳棳頃╇媹雼�. BofA 韽熂鞐愳劀電� 9鞗� 16鞚� "Immunology: Creating the next blockbuster in I&I" 韺剱 韱犽鞐� 彀胳劃頃╇媹雼�. 鞗轨簮鞀ろ姼電� 須岇偓鞚� Investor Relations 鞗鬼帢鞚挫鞐愳劀 雼れ嫓氤搓赴搿� 鞝滉车霅╇媹雼�.
Protagonist Therapeutics (NASDAQ:PTGX) a annonc茅 sa participation 脿 trois grandes conf茅rences investisseurs en septembre 2025. Le PDG Dinesh V. Patel, Ph.D., assistera au Citi's 2025 Biopharma Back to School Summit (2-3 septembre), au H.C. Wainwright 27th Annual Global Investment Conference (8-10 septembre) et au BofA 11th Annual World Medical Innovation Forum (15-17 septembre).
Le CEO prendra part 脿 des 芦 fireside chats 禄 lors des 茅v茅nements Citi et H.C. Wainwright, pr茅vus respectivement le 3 et le 9 septembre. Lors du forum BofA, il participera 脿 une table ronde intitul茅e "Immunology: Creating the next blockbuster in I&I" le 16 septembre. Les webcasts seront disponibles en replay sur la page Investor Relations de la soci茅t茅.
Protagonist Therapeutics (NASDAQ:PTGX) gab bekannt, dass es im September 2025 an drei gro脽en Investorenkonferenzen teilnehmen wird. CEO Dinesh V. Patel, Ph.D., wird am Citi's 2025 Biopharma Back to School Summit (2.鈥�3. September), am H.C. Wainwright 27th Annual Global Investment Conference (8.鈥�10. September) und am BofA 11th Annual World Medical Innovation Forum (15.鈥�17. September) teilnehmen.
Der CEO wird bei den Veranstaltungen von Citi und H.C. Wainwright an sogenannten Fireside Chats teilnehmen, die jeweils f眉r den 3. bzw. 9. September angesetzt sind. Auf dem BofA-Forum wird er am 16. September an einer Podiumsdiskussion mit dem Titel "Immunology: Creating the next blockbuster in I&I" teilnehmen. Webcasts stehen auf der Investor-Relations-Seite des Unternehmens zum Abruf bereit.
- None.
- None.
NEWARK, CALIFORNIA / / August 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in multiple investment bank conferences taking place in September.
Citi's 2025 Biopharma Back to School Summit; Boston, MA - September 2-3, 2025
Format: Fireside Chat
Day/Time: Wednesday, September 3 at 9:45 A.M. ET
Webcast: https://kvgo.com/2025-biopharma-back-to-school-conference/protagonist-therapeutics-inc-sep-2025
H.C. Wainwright 27th Annual Global Investment Conference; New York, NY - September 8-10, 2025
Format: Fireside Chat
Day/Time: Tuesday, September 9 at 11:30 A.M. ET
Webcast: https://journey.ct.events/view/2f5c929c-0a3b-473f-a149-bcc3e8c0ed5f
BofA 11th Annual World Medical Innovation Forum; Boston, MA - September 15-17, 2025
Panel Title: Immunology: Creating the next blockbuster in I&I
Day/Time: Tuesday, September 16
If you are interested in meeting with the Protagonist team during the conferences, please reach out to your respective conference representative.
A replay of the presentations will be available on the Company's webpage for one year following the event.
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application (NDA) for icotrokinra submitted to the FDA in July and the NDA submission for rusfertide is expected by end of 2025. Icotrokinra (formerly, JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor ("IL-23R") is licensed to J&J Innovative Medicines ("JNJ"), formerly Janssen Biotech, Inc. Following icotrokinra's joint discovery by Protagonist and JNJ scientists pursuant to the companies' IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at .
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
[email protected]
Media Contact
Virginia Amann, Founder/CEO
+1 833 500 0061 ext 1
ENTENTE Network of Companies
[email protected]
SOURCE: Protagonist Therapeutics
View the original on ACCESS Newswire
FAQ
When is Protagonist Therapeutics (PTGX) presenting at Citi's 2025 Biopharma Summit?
Where can I watch Protagonist Therapeutics' (PTGX) H.C. Wainwright conference presentation?
What type of presentation will PTGX give at the BofA Medical Innovation Forum 2025?
How long will Protagonist Therapeutics' conference presentations be available for replay?
